Press "Enter" to skip to content

Analysis of Glucagon like Peptide 1 (GLP – 1) Agonists Market 2019-2024: Industry Trends, Share, Size, Price, Revenue, Business Strategy, Production Technology Forecast to 2024

Glucagon

The “Glucagon like Peptide 1 (GLP – 1) Agonists Market” 2019 report provides market size (value and volume), market share, growth rate by types, applications, and combines both qualitative and quantitative methods to make micro and macro forecasts in different regions or countries. Glucagon like Peptide 1 (GLP – 1) Agonists Market report also aims to provide useful and comprehensive insights into current market trends and future growth scenarios. Glucagon like Peptide 1 (GLP – 1) Agonists market report contains information like SWOT analysis, business highlights, strength, weakness, threats and opportunities of industry.

Top Manufacturers of Glucagon like Peptide 1 (GLP – 1) Agonists Market Are:

  • NovoNordisk
  • Sanofi
  • Eli Lilly
  • AstraZeneca

    Get a Sample Copy of the Report – https://www.industryresearch.co/enquiry/request-sample/13999732

    Market Overview:

  • The glucagon-like peptide-1 (GLP-1) agonists market is expected to see a considerable amount of growth during the forecast period. The increase is mainly attributed to the improved efficiency of GLP-1.
  • Increasing diabetes prevalence in established and emerging countries is expected to drive the market. The increase in the diabetic population over the years is due to the overall effect of individual-level factors, like the increasing median age of the population and health factors, including increasing rates of obesity and inactivity levels among people.
  • In addition, lowering birth rates, along with increasing life expectancy, in countries like Japan, Italy, Germany, and France which have a high percentage of the geriatric population, are expected to drive the growth of the market.Novo Nordisk Victoza held a 55% market share in the GLP-1 agonist market in 2017, but it is expected that Eli Lilly’s Trulicity will dominate the market during the forecast period.

    Scope of the Report:

  • The market is segmented by the drug (Exenatide, Liraglutide, Dulaglutide, Lixisenatide), by brand (Byetta, Bydureon, Victoza, Trulicity, Lyxumia) and by geography.

    Glucagon like Peptide 1 (GLP – 1) Agonists Market Report Answers the Following Questions:

    • What will the market size and the growth rate be in 2024?
    • What are the key factors driving the global Glucagon like Peptide 1 (GLP – 1) Agonists market?
    • What are the key market trends impacting the growth of the global Glucagon like Peptide 1 (GLP – 1) Agonists market?
    • What are the challenges to market growth?
    • Who are the key vendors in the global Glucagon like Peptide 1 (GLP – 1) Agonists market?
    • What are the market opportunities and threats faced by the vendors in the global Glucagon like Peptide 1 (GLP – 1) Agonists market?
    • Trending factors influencing the market shares of the relevant regions.
    • What are the key outcomes of the five forces analysis of the global Glucagon like Peptide 1 (GLP – 1) Agonists market?

    For More Information or Query or Customization Before Buying, Visit at – https://www.industryresearch.co/enquiry/pre-order-enquiry/13999732

    Key Market Trends: – Constant Global Trend of High Diabetes Prevalence

    The sales of GLP-1 are directly proportional to the global trend of high diabetes prevalence.
    For instance, the percentages of type 2 diabetes in a few significant countries are as follows: China 22.8%, Oman 17.2%, Malaysia 12.9%, and so on.
    It is estimated, worldwide, that approximately USD 8.39 billion is spent on diabetes. The growth in the number of middle-class households, as well as increasing per capita income in these countries, are expected to result in better spending power in general, thereby helping to drive the market during the forecast period (2019-2024).
    Along with this, a few critical factors, such as advanced healthcare infrastructure, technological advancement, and availability of skilled medical professionals, are likely to play paradigm shifting roles in the overall growth of this market.

    North America to Dominate the Market in Terms of Revenue

    North America accounts for 77% of the overall GLP-1 market and is expected to witness a growth rate of 6.53%, during the forecast period.
    In the Middle East & Africa, the GLP-1 market is expected to see high growth during the forecast period, with a CAGR of 25.08%.
    In Asia-Pacific, according to the International Diabetes Federation, Japan and Australia have the highest per capita expenditure, of upwards of USD 3,000. However, China and India have the highest diabetes prevalence.

    Market Dynamics: –

    • Drivers: (Developing regions and growing markets)
    • Limitations: (Regional, Key Player facing Issues, Future Barriers for growth)
    • Opportunities: (Regional, Growth Rate, Competitive, Consumption)

    The report provides key statistics on the market status of the Glucagon like Peptide 1 (GLP – 1) Agonists Market manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the Glucagon like Peptide 1 (GLP – 1) Agonists.

    Purchase this Report (Price 5000 USD for single user license) – https://www.industryresearch.co/purchase/13999732

    Report Objectives:

    • Analyzing the size of the Glucagon like Peptide 1 (GLP – 1) Agonists market on the basis of value and volume.
    • Accurately calculating the market segments, consumption, and other dynamic factors of different sections of the global Glucagon like Peptide 1 (GLP – 1) Agonists market.
    • Determining the key dynamics of the Glucagon like Peptide 1 (GLP – 1) Agonists market.
    • Highlighting significant trends of the Glucagon like Peptide 1 (GLP – 1) Agonists market in terms of manufacture, revenue, and sales.
    • Deeply summarizing top players of the Glucagon like Peptide 1 (GLP – 1) Agonists market and showing how they compete in the industry.
    • Studying industry processes and costs, product pricing, and various trends related to them.
    • Displaying the performance of different regions and countries in the global Glucagon like Peptide 1 (GLP – 1) Agonists market.

    Detailed TOC of Glucagon like Peptide 1 (GLP – 1) Agonists Market Report 2019-2024:

    1 INTRODUCTION
    1.1 Study Deliverables
    1.2 Study Assumptions
    1.3 Scope of the Study

    2 RESEARCH METHODOLOGY

    3 EXECUTIVE SUMMARY

    4 MARKET DYNAMICS
    4.1 Market Overview
    4.2 Drivers
    4.3 Restraints
    4.4 Porter’s Five Forces Analysis
    4.4.1 Bargaining Power of Suppliers
    4.4.2 Bargaining Power of Consumers
    4.4.3 Threat of New Entrants
    4.4.4 Threat of Substitute Products and Services
    4.4.5 Intensity of Competitive Rivalry

    5 MARKET SEGMENTATION
    5.1 By Drug
    5.1.1 Exenatide
    5.1.1.1 Byetta (Value and Volume 2012-2024)
    5.1.1.2 Bydureon (Value and Volume 2012-2024)
    5.1.2 Liraglutide
    5.1.2.1 Victoza (Value and Volume 2012-2024)
    5.1.3 Lixisenatide
    5.1.3.1 Lyxumia (Value and Volume 2012-2024)
    5.1.4 Dulaglutide
    5.1.4.1 Trulicity (Value and Volume 2012-2024)
    5.2 Geography
    5.2.1 North America
    5.2.1.1 US (Value and Volume 2012-2024)
    5.2.1.1.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
    5.2.1.1.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
    5.2.1.2 Canada (Value and Volume 2012-2024)
    5.2.1.2.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
    5.2.1.2.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
    5.2.1.3 Rest of North America (Value and Volume 2012-2024)
    5.2.1.3.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
    5.2.1.3.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
    5.2.2 Europe
    5.2.2.1 Germany (Value and Volume 2012-2024)
    5.2.2.1.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
    5.2.2.1.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
    5.2.2.2 Spain (Value and Volume 2012-2024)
    5.2.2.2.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
    5.2.2.2.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
    5.2.2.3 Italy (Value and Volume 2012-2024)
    5.2.2.3.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
    5.2.2.3.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
    5.2.2.4 France (Value and Volume 2012-2024)
    5.2.2.4.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
    5.2.2.4.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
    5.2.2.5 UK (Value and Volume 2012-2024)
    5.2.2.5.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
    5.2.2.5.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
    5.2.2.6 Russia (Value and Volume 2012-2024)
    5.2.2.6.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
    5.2.2.6.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
    5.2.2.7 Rest of Europe (Value and Volume 2012-2024)
    5.2.2.7.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
    5.2.2.7.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
    5.2.3 Asia-Pacific
    5.2.3.1 Japan (Value and Volume 2012-2024)
    5.2.3.1.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
    5.2.3.1.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
    5.2.3.2 China (Value and Volume 2012-2024)
    5.2.3.2.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
    5.2.3.2.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
    5.2.3.3 Australia (Value and Volume 2012-2024)
    5.2.3.3.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
    5.2.3.3.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
    5.2.3.4 India (Value and Volume 2012-2024)
    5.2.3.4.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
    5.2.3.4.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
    5.2.3.5 South Korea (Value and Volume 2012-2024)
    5.2.3.5.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
    5.2.3.5.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
    5.2.3.6 Malaysia (Value and Volume 2012-2024)
    5.2.3.6.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
    5.2.3.6.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
    5.2.3.7 Indonesia (Value and Volume 2012-2024)
    5.2.3.7.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
    5.2.3.7.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
    5.2.3.8 Thailand (Value and Volume 2012-2024)
    5.2.3.8.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
    5.2.3.8.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
    5.2.3.9 Philippines (Value and Volume 2012-2024)
    5.2.3.9.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
    5.2.3.9.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
    5.2.3.10 Rest of Asia-Pacific (Value and Volume 2012-2024)
    5.2.3.10.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
    5.2.3.10.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
    5.2.4 Latin America
    5.2.4.1 Brazil (Value and Volume 2012-2024)
    5.2.4.1.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
    5.2.4.1.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
    5.2.4.2 Mexico (Value and Volume 2012-2024)
    5.2.4.2.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
    5.2.4.2.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
    5.2.4.3 Rest of Latin America (Value and Volume 2012-2024)
    5.2.4.3.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
    5.2.4.3.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
    5.2.5 Middle East & Africa
    5.2.5.1 South Africa (Value and Volume 2012-2024)
    5.2.5.1.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
    5.2.5.1.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
    5.2.5.2 Saudi Arabia (Value and Volume 2012-2024)
    5.2.5.2.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
    5.2.5.2.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
    5.2.5.3 Oman (Value and Volume 2012-2024)
    5.2.5.3.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
    5.2.5.3.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
    5.2.5.4 Egypt (Value and Volume 2012-2024)
    5.2.5.4.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
    5.2.5.4.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
    5.2.5.5 Iran (Value and Volume 2012-2024)
    5.2.5.5.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
    5.2.5.5.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
    5.2.5.6 Rest of Middle East & Africa (Value and Volume 2012-2024)
    5.2.5.6.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
    5.2.5.6.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)

    6 MARKET INDICATORS
    6.1 Type-1 Diabetes Population (2012-2024)
    6.2 Type-2 Diabetes Population (2012-2024)

    7 COMPETITIVE LANDSCAPE
    7.1 COMPANY PROFILES
    7.1.1 Novo Nordisk
    7.1.2 Sanofi
    7.1.3 Eli Lilly
    7.1.4 AstraZeneca
    7.2 MARKET SHARE ANALYSIS
    7.2.1 Novo Nordisk
    7.2.2 Sanofi
    7.2.3 Eli Lilly
    7.2.4 AstraZeneca

    8 MARKET OPPORTUNITIES AND FUTURE TRENDS

     

    Contact Us:

    Name: Ajay More

    Phone: US +14242530807/ UK +44 20 3239 8187

    Email: [email protected]

    Our Other Reports:

    Global Enzyme-Linked Immunosorbent Assay Market 2019-2026 | Size, Share, Future Demands, Development Strategy, Sales-Revenue, Growth Factors, Industry Updates and Key Players Analysis Available at Industry Research Biz

    Blockchain In Infrastructure Market 2019: Global Industry Trends, Future Growth, Regional Overview, Market Share, Size, Revenue, and Forecast Outlook till 2024,

    Plum Seed Oil Market 2019 Size, Share, Global Growth Factors, Future Trends, Opportunities, and Regional Outlook Forecast to 2023

    Security Analytics Market 2019-2024 Top Countries Data, Business Expansion Plans, Present Demands, Driving Factors, Rising Status of Key Players

  • Be First to Comment

    Leave a Reply

    Your email address will not be published. Required fields are marked *